This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Importance and Implications

E. Magnus Ohman, MD; Barbara E. Tardiff, MD

JAMA. 1997;277(6):495-497.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Up to 1 million patients annually may be undergoing percutaneous coronary revascularization with procedures including angioplasty, stent implantation, and atherectomy by the end of this decade.¹ Periprocedural myocardial infarction (MI) may occur in up to 14% of patients undergoing these procedures.^2,3 In the late 1980s, transient elevations of cardiac enzymes, such as creatine kinase (CK), were shown to occur relatively often despite a lack of symptoms indicative of MI.^4-6 Limited, short-term follow-up of small numbers of patients suggested that there was no increased risk of late adverse events in patients with such elevations.^4,5

See also p 461.

In the early 1990s, several new antithrombotic therapies and devices were tested prospectively in patients undergoing percutaneous interventions.^2,7 Transient elevations in cardiac markers, some similar to levels seen in a typical MI, were shown to occur in 20% to 40% of patients.^8-10 Later examination of several large . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Cardiology, Department of Medicine (Dr Ohman), and Division of Cardiothoracic Anesthesia, Department of Anesthesiology (Dr Tardiff), Duke University Medical Center, Durham, NC.

Footnotes
Reprints: E. Magnus Ohman, MD, Duke Clinical Research Institute, 2024 W Main St, Bay A-1, Durham, NC 27705.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?